Viewing Study NCT02332512


Ignite Creation Date: 2025-12-26 @ 11:07 AM
Ignite Modification Date: 2026-02-25 @ 9:48 PM
Study NCT ID: NCT02332512
Status: UNKNOWN
Last Update Posted: 2017-02-24
First Post: 2015-01-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module